Relief Therapeutics · ISIN: CH1251125998

Relief Therapeutics Publishes 2025 Half-Year Report

Relief Therapeutics Publishes 2025 Half-Year Report GENEVA (AUG. 14, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year r......

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 14.08.2025 | 07:00
14 August 2025 07:00AM
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Publishes 2025 Half-Year Report GENEVA (AUG. 14, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year r......
Relief Therapeutics
© EQS Newswire
14 August 2025 01:20AM
Relief Therapeutics Publishes 2025 Half-Year Report
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a co...
Relief Therapeutics
© ACCESSWIRE
11 August 2025 07:00AM
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Holding SA / Key word(s): Half Year Results Relief Therapeutics Advances Publication of 2025 Half-Year Report 11.08.2025 / 07:00 CET/CEST Relief Therapeutics Advances Publication of 2025 Half-Year Report   GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relie......
Relief Therapeutics
© EQS Newswire
11 August 2025 01:20AM
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025...
Relief Therapeutics
© ACCESSWIRE
29 July 2025 07:00AM
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, ......
Relief Therapeutics
© EQS Newswire
29 July 2025 01:20AM
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disordersBusiness combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech companyBinding term sheet signed; transaction subject to customary...
Relief Therapeutics
© ACCESSWIRE
20 June 2025 07:00AM
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011   GENEVA (June 20, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial r......
Relief Therapeutics
© EQS Newswire
20 June 2025 01:20AM
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease...
Relief Therapeutics
© ACCESSWIRE
12 June 2025 11:00AM
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Annual General Meeting 12.06.2025 / 11:00 CET/CEST Relief Therapeutics Announces Results of Annual General Meeting  Shareholders approved all proposals by a large majority GENEVA (June 12, 2025) – RELIEF THERAPEUTICS Holding ......
Relief Therapeutics
© EQS Newswire
12 June 2025 06:17AM
Relief Therapeutics Announces Results of Annual General Meeting
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, toda...
Relief Therapeutics
© ACCESSWIRE
22 May 2025 07:00AM
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011  GENEVA (May 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U......
Relief Therapeutics
© EQS Newswire
22 May 2025 01:20AM
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has grant...
Relief Therapeutics
© ACCESSWIRE
15 May 2025 07:00AM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Publishes 2025 Annual General Meeting Agenda 15.05.2025 / 07:00 CET/CEST Relief Therapeutics Publishes 2025 Annual General Meeting Agenda GENEVA (MAY 15, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharma......
Relief Therapeutics
© EQS Newswire
15 May 2025 01:20AM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to...
Relief Therapeutics
© ACCESSWIRE
10 April 2025 07:00AM
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update GENEVA (APR. 10, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report an......
Relief Therapeutics
© EQS Newswire
10 April 2025 01:20AM
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update. In his annual l...
Relief Therapeutics
© ACCESSWIRE
06 March 2025 07:00AM
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion GENEVA (March 6, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussi......
Relief Therapeutics
© EQS Newswire
06 March 2025 01:15AM
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussions regarding a potential merger with Renexxion, I...
Relief Therapeutics
© ACCESSWIRE
11 February 2025 07:00AM
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 11.02.2025 / 07:00 CET/CEST Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Patent Secures Protection for RLF-TD011 in Epidermolysi......
Relief Therapeutics
© EQS Newswire
11 February 2025 01:20AM
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rar...
Relief Therapeutics
© ACCESSWIRE
22 January 2025 07:00AM
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE® Rights ex-USSale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharm......
Relief Therapeutics
© EQS Newswire
22 January 2025 01:20AM
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Sale of GOLIKE® Rights Outside the U.S. to NutrisensRelief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
Relief Therapeutics
© ACCESSWIRE
27 December 2024 07:00AM
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Holding SA / Key word(s): Merger Relief Therapeutics Provides Update on Potential Transaction with Renexxion 27.12.2024 / 07:00 CET/CEST Relief Therapeutics Provides Update on Potential Transaction with Renexxion GENEVA (DEC. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)......
Relief Therapeutics
© EQS Newswire
27 December 2024 01:20AM
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today provided an update on the potential reverse merger with Renexxion, In...
Relief Therapeutics
© ACCESSWIRE
16 December 2024 07:00AM
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial 16.12.2024 / 07:00 CET/CEST Relief Therapeutics Announces Final Readout of PKU GOLIKE® Clinical Trial Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PK......
Relief Therapeutics
© EQS Newswire
16 December 2024 01:20AM
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU GOLIKE ®GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF )(OTCQB:RLFTF )(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company commi...
Relief Therapeutics
© ACCESSWIRE
13 December 2024 11:00PM
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA (DEC. 13, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering inn......
Relief Therapeutics
© EQS Newswire
13 December 2024 05:25PM
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB QuotationGENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and...
Relief Therapeutics
© ACCESSWIRE
11 November 2024 07:00AM
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa GENEVA (NOV. 11, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, t......
Relief Therapeutics
© EQS Newswire
11 November 2024 01:20AM
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive final results from its proof-of-concept, investig...
Relief Therapeutics
© ACCESSWIRE
04 November 2024 07:00AM
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger   GENEVA (NOV. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced i......
Relief Therapeutics
© EQS Newswire
04 November 2024 01:20AM
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Ren...
Relief Therapeutics
© ACCESSWIRE
29 October 2024 07:00AM
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE 29.10.2024 / 07:00 CET/CEST Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE GENEVA (OCT. 29, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, O......
Relief Therapeutics
© EQS Newswire
29 October 2024 02:20AM
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseas...
Relief Therapeutics
© ACCESSWIRE
25 October 2024 07:00AM
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA (OCT. 25, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a b......
Relief Therapeutics
© EQS Newswire
25 October 2024 01:20AM
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov...
Relief Therapeutics
© ACCESSWIRE
21 October 2024 07:00AM
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment GENEVA (OCT. 21, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un......
Relief Therapeutics
© EQS Newswire
08 October 2024 07:00AM
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa GENEVA (OCT. 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare disea......
Relief Therapeutics
© EQS Newswire
08 October 2024 01:20AM
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced promising preliminary results from its proof-of-concept, inv...
Relief Therapeutics
© ACCESSWIRE
04 October 2024 07:00AM
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria GENEVA (OCT. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseas......
Relief Therapeutics
© EQS Newswire
04 October 2024 01:20AM
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
GENEVA, SWITZERLAND / ACCESSWIRE / October 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported positive topline results from its proof-of-concept clinical s...
Relief Therapeutics
© ACCESSWIRE
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r......
Relief Therapeutics
© EQS Newswire
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r......
Relief Therapeutics
© EQS Newswire
23 September 2024 01:20AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA, SWITZERLAND / ACCESSWIRE / September 23, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will receive a $2 million milestone payment from SWK...
Relief Therapeutics
© ACCESSWIRE

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.